Contact Jacoby & Meyers
Dangerous Drug Lawyers
Call us Today 800-977-5614

Campath is a monoclonal antibody drug, which was approved by the FDA in 2001 to treat cutaneous T-cell Lymphoma (CTCL) and T-cell Lymphoma. It is manufactured by Schering and Genzyme Corp., and doctors have also prescribed Campath for the off-label use of treating multiple sclerosis (MS).
In 2005, the manufacturers of Campath suspended a trial after three cases of serious side effects were recorded. In this study, researchers found three cases of Idiopathic Thrombocytopenic Purpura (ITP). ITP occurs when patients experience a low platelet count, which can cause abnormal bleeding. The manufacturer was then required to notify doctors and patients about these serious risks.
Along with ITP, Campath has also been linked to serious conditions such as cardiac arrest, myocardial infarction, cardiac arrhythmias, respiratory arrest, pulmonary infiltrates, syncope, autoimmune disease, hypotension, shortness of breath and bronchospasm.
Patients taking Campath should see a doctor if one of these serious side effects occurs:
More Common:
Less common side effects:
Rare side effects:
Incidence not determined:
Other side effects associated with Campath are:
Lawyer Advertising. This website is designed for general information only, and in no way is intended to constitute legal advice nor the formation of a lawyer/client relationship without a signed, written agreement. Testimonials or endorsements do not constitute a guarantee, warranty, or prediction regarding the outcome of your legal matter. You pay no fees or costs unless we recover for you. This website contains dramatizations. Prior results are not a guarantee of a future outcome. Jacoby & Meyers does not accept all cases and works cooperatively with co-counsel and/or other law firms with whom it has joint agreements who might potentially handle your cases. We look forward to helping you with your claim.
© 2012-2025 Jacoby & Meyers. All rights reserved.